Eventide Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Eventide Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-130,000	Closed	-$6.55M	–	150
2018 Q3	$6.55M	Hold	130,000	–	–	0.24%	95
2018 Q2	$7.78M	Hold	130,000	–	–	0.32%	81
2018 Q1	$5.95M	Hold	130,000	–	–	0.28%	87
2017 Q4	$5.18M	Hold	130,000	–	–	0.27%	83
2017 Q3	$5.2M	Sell	130,000 -39,000	-23%	-$1.69M	0.29%	76
2017 Q2	$7.28M	Sell	169,000 -201,000	-54%	-$7.15M	0.45%	57
2017 Q1	$11.6M	Sell	370,000 -75,000	-17%	-$2.01M	0.77%	46
2016 Q4	$11.2M	Hold	445,000	–	–	0.73%	48
2016 Q3	$11M	Sell	445,000 -130,000	-23%	-$2.94M	0.67%	48
2016 Q2	$11.7M	Hold	575,000	–	–	0.72%	49
2016 Q1	$8.77M	Buy	575,000 +77,000	+15%	+$1M	0.49%	57
2015 Q4	$6.69M	Buy	498,000 +149,400	+43%	+$2.31M	0.33%	72
2015 Q3	$4.89M	Buy	348,600 +62,000	+22%	+$1.15M	0.28%	75
2015 Q2	$4.87M	Hold	286,600	–	–	0.26%	75
2015 Q1	$3.46M	Buy	286,600 +29,600	+12%	+$280K	0.26%	77
2014 Q4	$2.13M	Hold	257,000	–	–	0.23%	77
2014 Q3	$2.23M	Buy	257,000 +16,400	+7%	+$148K	0.31%	67
2014 Q2	$2.63M	Buy	240,600 +25,100	+12%	+$224K	0.36%	70
2014 Q1	$1.93M	Buy	+215,500	New	+$1.98M	0.3%	69

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Eventide Asset Management's SUPN Position: Q4 2018 in Review

Eventide Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 130,000 shares — an estimated $6.55M sold.

Eventide Asset Management first reported a position in SUPN in Q1 2014 and held it in 19 quarters. The position peaked at $11.7M in Q2 2016. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

Eventide Asset Management reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Eventide Asset Management sold 130,000 Supernus Pharmaceuticals shares in Q4 2018, an estimated $6.55M.
Eventide Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 19 quarters.
Eventide Asset Management's Supernus Pharmaceuticals position peaked at $11.7M in Q2 2016.
274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Eventide Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.